-----BEGIN PRIVACY-ENHANCED MESSAGE-----Proc-Type: 2001,MIC-CLEAROriginator-Name: webmaster@www.sec.govOriginator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQABMIC-Info: RSA-MD5,RSA, QpF9FBFQKGheoAbNClXA0rtZz+DxvPy0rHaaZZ6EDoUFLJQ0KIE4x6yi2Qk282Qe CRJvt3oHpU+VyeuzrWu32A==

0000950123-10-078388.txt : 201008170000950123-10-078388.hdr.sgml : 2010081720100817121417ACCESSION NUMBER:0000950123-10-078388CONFORMED SUBMISSION TYPE:DEFA14APUBLIC DOCUMENT COUNT:58FILED AS OF DATE:20100817DATE AS OF CHANGE:20100817EFFECTIVENESS DATE:20100817

FILER:

COMPANY DATA:COMPANY CONFORMED NAME:OSTEOTECH INCCENTRAL INDEX KEY:0000874734STANDARD INDUSTRIAL CLASSIFICATION:SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]IRS NUMBER:133357370STATE OF INCORPORATION:DEFISCAL YEAR END:1231

FILING VALUES:FORM TYPE:DEFA14ASEC ACT:1934 ActSEC FILE NUMBER:001-34612FILM NUMBER:101022375

BUSINESS ADDRESS:STREET 1:51 JAMES WAYCITY:EATONTOWNSTATE:NJZIP:07724BUSINESS PHONE:7325422800

MAIL ADDRESS:STREET 1:51 JAMES WAYCITY:EATONTOWNSTATE:NJZIP:07724

DEFA14A1c59872defa14a.htmDEFA14A

defa14a

Table of Contents

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section14(a) of the
Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

o

Check the appropriate box:

o Preliminary Proxy Statement

o Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2))

o Definitive Proxy Statement

o Definitive Additional Materials

Soliciting Material Under Rule14a-12

Osteotech, Inc.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No Fee required

o Fee computed on table below per Exchange Act Rules14a-6(i)(1) and 0-11.

1)

Title of each class of securities to which transaction applies:

2)

Aggregate number of securities to which transaction applies:

3)

Per unit price or other underlying value of transaction computed pursuant to Exchange ActRule0-11 (Set forth the amount on which the filing fee is calculated and state how it wasdetermined):

4)

Proposed maximum aggregate value of transaction:

5)

Total fee paid:

o

Fee paid previously with preliminary materials:

o Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) andidentify the filing for which the offsetting fee was paid previously. Identify the previousfiling by registration statement number, or the Form or Schedule and the date of its filing.

1)

Amount Previously Paid:

2)

Form, Schedule or Registration Statement No.:

3)

Filing Party:

4)

Date Filed:

TABLE OF CONTENTS

EXPLANATORY NOTEExhibitA: Letter to physiciansExhibitB: Letter to distributorsExhibitC: Letter to vendorsExhibitD: Comments from Sam Owusu-Akyaw, Osteotechs Chief Executive Officer, at theOsteotech employee meeting held on August17, 2010ExhibitE: Osteotechs PowerPoint presentation from the Osteotech employee meeting held on August17, 2010ExhibitF: Medtronics PowerPoint presentation from the Osteotech employee meeting held on August17, 2010

Table of Contents

EXPLANATORY NOTE

Filed Documents

This filing consists of the following documents relating to the proposed acquisition of Osteotech,Inc. (Osteotech) by Medtronic, Inc. (Medtronic):

ExhibitA:

Letter to physicians

ExhibitB:

Letter to distributors

ExhibitC:

Letter to vendors

ExhibitD:

Comments from Sam Owusu-Akyaw, Osteotechs Chief Executive Officer, at theOsteotech employee meeting held on August17, 2010

ExhibitE:

Osteotechs PowerPoint presentation from the Osteotech employee meeting held onAugust17, 2010

ExhibitF:

Medtronics PowerPoint presentation from the Osteotech employee meeting held onAugust17, 2010

Additional Information about the Proposed Transaction and Where You Can Find It

Osteotech intends to file with the Securities and Exchange Commission (the SEC) preliminary anddefinitive proxy statements and other relevant materials in connection with the proposedacquisition of Osteotech by Medtronic. The definitive proxy statement will be mailed to Osteotechstockholders. BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS WITH RESPECT TO THE TRANSACTION,INVESTORS AND SECURITY HOLDERS OF OSTEOTECH ARE URGED TO READ THE PROXY STATEMENT AND THE OTHERRELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUTTHE TRANSACTION, OSTEOTECH AND MEDTRONIC. Investors and security holders may obtain free copies ofthese documents (when they are available) and other documents filed with the SEC at the SECs website at www.sec.gov. In addition, investors and security holders may obtain free copies of thedocuments filed with the SEC by accessing Osteotechs website at www.osteotech.com or by writingOsteotech at 51 James Way, Eatontown, New Jersey, 07724.

Information Regarding Participants

Osteotech, Medtronic and their respective directors, executive officers and certain other membersof management and employees may be soliciting proxies from Osteotech stockholders in favor of themerger. Information regarding the persons who may, under the rules of the SEC, be consideredparticipants in the solicitation of the Osteotech stockholders in connection with the proposedmerger will be set forth in the proxy statement when it is filed with the SEC. You can findinformation about Medtronics executive officers and directors in its definitive proxy statementfiled with the SEC on July16, 2010. You can obtain a free copy of this document at the SECs website at www.sec.gov, or by accessing Medtronicss website at www.Medtronic.com and clicking on theInvestors link. You can find information about Osteotechs executive officers and directors in itsdefinitive proxy statement filed with the SEC August3, 2010. You can obtain a free copy of thisdocument at the SECs web site at www.sec.gov or by accessing Osteotechs website atwww.osteotech.com or by writing Osteotech at 51 James Way, Eatontown, New Jersey, 07724.

Table of Contents

ExhibitA

Letter to Physicians

As you may have read earlier today we announced in a press release that we have signed an agreementwith Medtronic to be acquired and integrated into their biologics business.

We wanted to reach out to you personally to share this news and briefly discuss the opportunitiesthat this transaction will create for our organization and the biologics industry. In addition, wewanted to thank you for the support you have given our products and technology over the years.

As a result of your loyalty to and belief in our family of products, we have successfullytransformed Osteotech from a basic tissue processing company to an emerging leader in the high-techbiologics market. Over the past 3+ years, we have built multiple technology platforms that supporta broad range of therapy-driven products that deliver superior clinical results to you and yourpatients. You have helped us build and maintain our market-leading position with our Grafton DBMfamily of products, and at the same time, your support has allowed us to gain valuable mind sharefor our newest products including MagniFuse Bone Grafts and Plexur Biocomposites.

We believe that Medtronic will carry forward our mission to develop leading-edge regenerativebiologics that will positively impact the lives of patients, enhance physicians capabilities todeliver superior surgical outcomes and enhance the gift of life to promote healing. We are veryproud of this next step we are embarking upon.

Once again, we want to thank you for all the support youve provided throughout the years. We haveworked tirelessly to build the greatest biologics platform available and to redefine leading-edgegrafting techniques. With your confidence and commitment to our technology, we have emerged as aleader in the biologics industry. We are confident that this combination of two world-classorganizations will provide continued benefits to the physician and patient communities we jointlyserve.

Please feel free to contact us directly with any questions; we look forward to utilizing our sharedhistory to build a bright future.

Table of Contents

ExhibitB

Letter to Distributors

As you may have read earlier today we announced in a press release that we have signed an agreementwith Medtronic to be acquired and integrated into their biologics business.

We wanted to reach out to you personally to share this news and our excitement about theopportunities that this transaction will create for our organization and the biologics industry.Thanks in no small part to your contributions we have successfully transformed Osteotech from abasic tissue processing company to an emerging leader in the high-tech biologics market. Over thepast 4years, we have built multiple technology platforms that support a broad range oftherapy-driven products that deliver superior clinical results to surgeons and their patients. Youhave helped us maintain our leading position in the market with our Grafton DBM family ofproducts, and at the same time, your efforts have allowed us to gain valuable market share for ournewest products including MagniFuse Bone Grafts and Plexur Biocomposites.

We are grateful for your hard work and loyalty and we hope we can count on your continued supportthrough this next phase. Please realize that this transaction will take time to close and we appealto you to continue to service your customers with the same level of care that youve alwaysexhibited.

We know that you may have many questions, and we encourage you to reach out to us directly. In theinterim, here are some key considerations to keep in mind:

Until the close of the transaction, Medtronic and Osteotech remain separate companies andtherefore business will be conducted as usual. We will continue to work with you to serveour customers and surgeons as we have since our doors opened more than 20years ago. We needyour continued support as we focus on customer service, ongoing product development andproduct sales.

There will be no immediate change in quotas, commissions or any sales-related processes. Weare focused on continuing to work with you and we hope to build upon our strong, existingrelationship. As such, we want encourage an interactive dialogue regarding how we maysupport you through this transition.

Once again, we want to thank you for all of your hard work and dedication over the years andcontinued support throughout this transaction. We look forward to continuing our relationship withyou as we grow.

Table of Contents

ExhibitC

As you may have read, Osteotech announced in a press release that it has signed a definitiveagreement with Medtronic, Inc. to be acquired and integrated into their biologics business.

As a key strategic supply partner, I wanted to personally communicate this exciting news to you andyour team. With your support, we have successfully transformed Osteotech from a tissue processingcompany to an emerging leader in the high tech biologics market. We have built a series oftechnology platforms that support a broad range of therapy-driven devices that deliver superiorresults for surgeons and their patients.

We believe that the strength of the Medtronic global distribution network will allow these devicesto reach their significant market potential and that you will benefit directly from this growth.While the exact timing for the completion of the merger is uncertain, we encourage you to beginplanning for opportunities that this transaction may create for you and your organization.

We are grateful for your support in the past and we need your continued support as we complete thisstrategic transaction.

We know that you have many questions and we encourage you to reach out to us directly. In theinterim, here are some key considerations to keep in mind:

Until the close of the transaction, Medtronic and Osteotech remain separate companies and;therefore, business will be conducted as usual.

You will continue to receive Purchase Orders from Osteotech and you will continue todeliver goods and services to our facilities.

We value your partnership and thank you in advance for your continued support throughout thistransition.

Table of Contents

ExhibitD:

All Hands Employee Meeting Comments
Sam Owusu-Akyaw

Good morning everyone, by now I believe you have all seen this mornings press release. Let me openmy comments by saying that transaction is based upon our mission statement focused on:

Developing technology to promote biological healing to restore function;

To be innovative with the gift of life and provide customer satisfaction;

To help our employees achieve professional growth;

And last, but not least to enhance the value of our shareholders investments.

With that in mind, Ive prepared a few comments for this morning that should help you betterunderstand this transaction.

First, thank you all for attending this impromptu company meeting, we appreciate your flexibility.Joining me today from Medtronic are Tom McGuinness, general manager of the biologics business andMike Nicoletta, who will be heading up integration activities at Medtronic.

Let me start by saying that, because of you, we have transformed Osteotech from being a basicprocessing company to a high-tech biologics company. As a result, Osteotech has uniquecharacteristics and skills compared with the metal companies, which make several of your skillsin high demand. We are hopeful that through this transaction, you will be able to continue to growprofessionally with a company like Medtronic. Medtronics global scale and scope across geographiesand functions in the medical device industry position it to provide additional opportunities forpersonal growth beyond that which Osteotech is able to offer.

This transaction is the culmination of the hard work that Osteotechs employees, domestic salesagents and international distributors have put in over the past 4years to execute a growthstrategy focused on new technology and procedure specific product development. Despite the enormityof the goal, you all remained focused on utilizing our assets to create therapy-driven productsthat deliver superior clinical results to our surgeon customers and their patients. Wesucceeded in achieving this goal and creating what we believe to be the greatest biologicsplatform. A platform that we believe can live up to its promise under the direction and support ofMedtronic.

As you have probably all read by now, we announced in a press release this morning that Medtronicwill be acquiring Osteotech for $6.50 per share in an all-cash transaction valued at approximately$123million. To shareholders, and most of you are shareholders, this means you will receive anapproximately 65% premium compared with yesterdays closing price. For your reference, from 2006through 2010 in similar transactions, the average premium to the previous days closing stock pricewas just 43%. We the management team and board of directors, believe this premium illustrates thestrong value of our organization and that this transaction represents the best step forward for allour stakeholders.

Table of Contents

In fact, we believe that this transaction is the natural, next step in the evolution of thecompany. Make no mistake, we were only successful in putting together this exciting corporatedevelopment because of your dedication and focus on achieving our long-term strategic goals.

We are excited that this acquisition can and will expand upon all of the work that youve done andextend the value of the biologics platforms that you have built. We are pleased that the spirit ofour mission as a company will live on.

I know that you will have many questions, and we will open the floor following some remarks fromthe Medtronic team. But before I turn the meeting over to Tom, I want to stress a few points.

First, we will be operating business as usual. Tomorrow will be no different from yesterday ortoday and we will continue to exceed the expectations of our customers and surgeons. We willcontinue to work closely with the international and domestic distributors and our vendors as wehave since our doors opened more than 20years ago. Plain and simple, we need your continuedsupport and I know you will put forth the same strong effort you put in everyday.

Second, we will be working closely with Medtronic regarding next steps for our employees and wewill provide you with updates as the process moves on.

Finally, over the next several days, we will be filing detailed documents with the SEC regardingthis transaction and we urge you, as shareholders, to review these materials. As we disclosed inthe press release this morning, this transaction is subject to shareholder and regulatory approval.Along with all other shareholders, you will receive a proxy statement asking for your vote.Currently, we expect the transaction to close sometime in the fourth quarter.

Thank you very much for your attention. Id like to now turn the floor over to Tom.

After Medtronic Comments

I would like to close this meeting with two important sentiments. First, we thank you, pure andsimple, for all of your hard work over the years.

Finally, as always, I have an open door policy and welcome any of your questions or concerns. Wewill continue to be available to answer your questions as the process moves on.

Table of Contents

ExhibitE

Employee CommunicationAugust17, 2010

Table of Contents

industrial way corridor neighbors helping neighborsFOOD DRIVE

Table of Contents

From Tissue Processor to Biologics Innovator1986 1991 2000 2005 2007 2009 2010 2011

Table of Contents

traditional allograft BONE AND SOFT

Table of Contents

graftondemineralized Bone Matrix (DBM)The Gold Standard in DBM

Table of Contents

GRAFTECHSTRUCTURAL ALLOGRAFTS

Table of Contents

15 MonthsPost Op

Table of Contents

PLEXUR

Table of Contents

PLEXURINNOVATIVE GRAFTING

Table of Contents

BONE GRAFT

Table of Contents

FACET

Table of Contents

BIO GENESIS

Table of Contents

GRAFTON in Spine

Table of Contents

GRAFTON Matrix Posterior Lumbar1 YearPost Op

Table of Contents

GRAFTONMatrix Strips Spinal Deformity

Table of Contents

GRAFTON A-Flex Acetabular RevisionImmediatePost Op6 MonthsPost Op

Table of Contents

GRAFTON Flex

Table of Contents

GRAFTON Gel Percutaneous Injection

Table of Contents

PLEXUR

Table of Contents

Plexur P WedgePre Op8 WeeksResumed NormalActivity

Table of Contents

Plexur P BlockPre Op3 MonthsResumed NormalActivity

Table of Contents

Plexur P CylinderPre Op3 MonthsResumed Normal Activity

Table of Contents

Time 0 Rabbit6 Months Rabbit

Table of Contents

PLEXURINOVATIVE GRAFTING

Table of Contents

Plexur M Shatzker VIPre Op Immediate Post Op 10 Months Post Op

Table of Contents

Plexur M Proximal Tibial Tumor44 WeeksPost Op21 WeeksPost Op7 WeeksPost OpImmediatePost Op

Table of Contents

Injectable Non-weight bearing Polyurethane platformPartA: Lysinetriisocyanate-polyethyleneglycol (LTI-PEG)PartB: Hardener (Polyol+ catalyst)Setting time:15 minutesBoneIn situ Bone/polymer foamSetting time:15 minutesHandling time:3-5 minutesIn situ Bone/polymer foam

Table of Contents

MAGNI FUSE BONE GRGFT

Table of Contents

Growth FactorsFull Array ofGrowth FactorsEmbedded inNatural HumanCollagenBMP 2,4,6,7TGF-?PDGFIGFNanotechnology

Table of Contents

MagniFuse Cervical & Thoracic

Table of Contents

MagniFuse PL3 Months Post Op 6 Months Post OpRapid and Solid Bone Formation

Table of Contents

Immediate Post Op 3 Months Post Op 6 Months Post OpRapid and Solid Bone Formation

Table of Contents

6-Months Post Op(3-Dimensional CT Reconstruction)

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Microstructure250x1,000x10,000x

Table of Contents

FilmWound RepairHuman Collagen Sponge TechnologyHernia Repair

Table of Contents

HCTHuman Collagen TechnologyMagniFuseBone GraftFacetLinxFusion TechnologyPlexurInnovative GraftingGraftonDemineralized Bone MatrixXpanseBone Insert

Table of Contents

ExhibitF:

Medtronic: Innovating for LifeTown Hall Meeting August17, 20101 | MDT Confidential

Table of Contents

The Early Years

Table of Contents

The Place to Be ... A Rich History of Leadership50 ~50 21,000+Diseases Treated Years of the Patents Awarded with Medtronic Medtronic Mission Products7M150,000+ $11BPatients Benefit fit Returned to from Medtronic Products Shareholders Products in Last 5 YearsAnnually

Table of Contents

Innovation Has Driven Growth and Success DrivenFY01 FY10CRDMCardioVascular cular$ Billions lllioi nss15.81614.6Physio Control 13.512.312 11.3 10.1Spinal 9.18 7.7 6.4 5.6Neuromodulation4Diabetes 0FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10Surgical Tech

Table of Contents

Global Diversification has Driven PerformanceEurope & FY01 Central AsiaJapanInternational Revenue IntlGreater China % of TotalRevenue8 40% $ BillionsOther Asia 6.565.6 5.2 4.4Canada4 3.7 30%3.3 2.9Middle East 2.31.9 1.9& Africa 2Latin America 0 20%FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10

Table of Contents

Leading Positions in Chronic Disease MarketsChronic Disease Epidemic:Focus Positions Us for Growth Large, Growing and Costly60% of deaths worldwide from chronic disease17% growth in chronic disease deaths by 2015of healthcare spending 75% on chronic disease

Table of Contents

Integrating Technology to Deliver InnovationLIFE SCIENCES Targeted Drug Delivery MaterialsENGINEERINGSCIENCES Power Sources Closed-Loop Systems MiniaturizationINFORMATION Connected Care ImagingTECHNOLOGY Navigation

Table of Contents

We Share a Patient-Centric MissionWe believe our first responsibility is to use technology to enhance the gift of life; to developtherapy-driven products that alleviate pain and promote biological healing and restore function.

Table of Contents

Together, We Will Be Better Positioned To:Drive awareness and demand for Biologics Offer distinctive product portfolio and pipelineCreate opportunities to develop breakthrough next-generation products Expand across treatmentareas Accelerate growth internationallyWith our shared expertise, innovation and values, we will enhance our ability to serve doctors andtheir patients and continue to fulfill our mission of alleviating pain, restoring health andextending life

Table of Contents

MedtronicTherapy PortfolioGrowth Factors DBMs SyntheticsGraftingINFUSE PROGENIX MASTERGRAFTBoneStructural Specialty TraditionalCAPSTONE Cortical Facet Dowel Allograft Bone ChipsAllograftCORNERSTONE Durepair PRECISION

Table of Contents

Therapy Portfolio OsteotechGrowth Factors DBMs SyntheticsGraftingINFUSE GRAFTON MASTERGRAFT MAGNIFUSE PLEXUR Bone PROGENIXStructural Specialty TraditionalCAPSTONE BioGenesis Allograft Bone ChipsAllograftCORNERSTONE Cortical Facet Dowel Tradl Allograft Graftech Durepair PRECISION FacetLinx,Xpanse

Table of Contents

Medtronic Biologics & Regenerative TherapiesDistinctive Capabilities Global Revenue $ MillionsWorld-class Biologics talent +37% 871806 833Gold-standard 701 commercial capabilities 571Drug/device combo 413 product development 257 expertise 95Industry-leading clinical and economic evidence FY03 04 05 06 07 08 09 10ELeading field scale High-growth focus Lean operating area within MDT, model delivers targetingincremental 179% RONA, well investments above MDT average

Table of Contents

Upside Remains in rhBMP-2 Franchise, and We Are Investing to Unlock New ApplicationsDental/CMF Current indicationsSinus Aug. /Alveolar CleftExt. Sockets Ongoing studies New/projected studiesRidge AugmentationMulti-level ACDF 8 anticipated IDEs Cervical (ACDF)focus on the most Adult Deformity difficultorthopedic(scoliosis)Spine healingAnterior Lumbar(ALIF)environmentsTransforaminalPostero Lateral Lumbar (TLIF)Unlock $2B $3BFusion (AMPLIFY)in revenuePostero Lateral potential Fusion (INFUSE)OrthopedicAcute, Open Tibia Del. HealingTibia FractureHind-foot Fusion13 | MDT Confidential

Table of Contents

Our Vision: Global Leader in Musculoskeletal Biologics & Regenerative TherapiesBroader Biologics sStem cell therapy y rhGDF-5Pain therapies Technologies Disc repairDiagnostics$1B Foundation NewBone grafting OpportunitiesSpine OrthopedicsU.S. Dental Global Next Generation Products

Table of Contents

Moving ForwardGuiding Principles to ensure seamless integration:3 Maintain business momentum during the integration period3 Understand and respect both cultures and how we operate3 Never compromise quality or delivery of customer supply3 Provide employees with frequent, direct and open communicationPost integration, our combined businesses will be positioned to offer a truly distinctive,world-class portfolio

Table of Contents

Q&A

GRAPHIC2c59872c5987256.gifGRAPHIC

begin 644 c59872c5987256.gifM1TE&.#EA^P!8`.8``+.RM)J:G?WEM_WJQ9*2E?KZ^ON\1/[VY_[Y\/JX./7UM]?S-=>WM[8F*C?+Q\OS6C.7EYH&!A965F(6%B8V-D.GIZ?O#5.+AXOW=HMW=MWOJQ(YV=H,7%QOW@J_S*;/O$6_N]2-G9VOS\_/W;FO[RVOJT*Z:FJ,'`PM75MUOO&8?W8D\W-SOS1?JZML-'1TO[NT:*BI,G(RJJJK+FXNK:UMZVLK[V\OJBHMJ_S2@Z"@H[JZO*2DI\_.T,"^P?O(9?JO'M_>W\+"Q+Z^P/W6D8F[RZO?O`3MK:VY^@HM?6U_R]4+>VN=C7V/W&:8^0MD\C'R:2BIL3#Q=33U=_?X(>'BZ>FJ:NLKM#/T;N[O?W/?^#@X:.CII>7FL3$MQ;>WN:RKKN/CX^CHZ.?GY^3CY.KJZ["PLO/S\^_N[_#O\.SL[(^/D_?W]\?(MR?CX^*>HJNCGY[^_P?3T]-O;W,S,S?#P\/W8F.3DY?JO'/___R'Y!```````M+`````#[`%@```?_@'\6@X2%AH>(B8J+C(T=?Y"1DI.4E9:7F)F:FYR=GI^@M?WZCI*6FIZBIJJNLK0^AL+&RL[2UH*VXN;J[J:^VO\#!PL.\Q00Q\2P#[G!E/(H94"=Q21!@HS$%"&YFL4$$#;/13`1AD*U.`UM_^P14`Z)]QNPP04#9\Q;@`@VK(M%%5_L\3;-&2-.#L>R>+Q'%P18`I5VE%"&%HBMM!E(X`QNL\#T7_*$`62@##8+0@BDI:-QK8]40E%Z$M#K9@!JM9+0@`(``\BUS>$XA!"C.@@`RD(`,QH$%6?XA#&>Z0:0`D80=2.$$+M)A`$VTI@#ID>0Q!LD#X;Q($&7^#"!K)`B3-G.`!94`P`)/_`X$L(`78H@$$D(`4&,``)C+"`!;"@&Z%CMG`I`8+?A[77M`R#X`''2]X?U'_&MJ0*".`MVN7.UX1Q5$QF77M'"0>00!:,[0`=``$W$&`$(PJ`!:YCV+!Z^+X!C.`%&/H$E"6[U!YF1H(24&V`)/_:X8&%@!!WPUPW7R,8VNO&-X.'AXO;V]X*`AMG8VMW7FXR*C]?6V+>VN&BX:$B>?FYX%_ACC+1@QP,CG=LH&\!+.;`!P$`-Q$`((@`%P,/,&"DP.0H[%3D8*#FB*#0H`0A.30$[`3,AISXRM-D@S%2@>/'@)JTMR"XL8.`3?`M%&!RI$^?!@\>'&G`M*E3IDF5/F5Z9"E3*"M6=)"!I(;_!D8+PHH=.U:!6`5HMTZI=R[:MV[=HR#]^_IL%X!`I.C-6;&2G"!@%0(*.,@;M(.PGB0T%%G@@?X2L-\@BABA""",%)*%A`9+XT(,CUR!1#@I;I")`$PKTL,,-M8O1@`#`![8"!`!Z@AP`XML,,).&"-TL$D'^;@M0`+(Y@.Z[;(`3J@`]8;"@3G&8`$]:`%O?-*SBA2"BXF@"0H`&9>,0F7PK3MUA00@'"@`&JHNP(?PJ&!3\CC`"F8E7[B:)8:0+!>`1R@`,L'A2DH`8'K&XM_M^(0%(&)"!LJ@?_%5H/85H*R,.0:&C(:UH7"R0#9(`T@*\(0EG[XMA@%,\`$.VL$$#MA!$NXX@1U,6-H6N&,!N[P)$PP7`%8@(3,%X(!&D&!0$RM&EA,XE*ED5XE0`7M0!P)YF\5.'(!]Q3O]S__0[(UMU=)0$:$P'(R!E$CMF=,V[1[MK0E]@9(JP%IME@`(5(``!O`L"TWH_TSJM?)H@C9&LA8"T%"JE5\`5M:2093J,E*4#F#A3+C((V6'OM:M?QZKY&+KT.;MK]VK'AIBM9,G&6"\H,OA?"MX5#9D`\,A=5$G'`I+Q]Q#[;R1*0A9K4[O!M&TT'`/6"?2''OZ?1P&4?(8V]L%Q?@/_J"3YC1;U9Q_SYCW!B`U@C]DRWOMY[4X1BQ`JRT%EQ4[^F/*4;1D)&,0\E`/63_ZL0FPP(,M2`#-=K"#29BT"1XH8PA&H!X8;L*!NK!%YVS8@95A@H@^S.$E@K@SF9W#"@CK%#0UP@QM4H-"?B@!%'2B`!C1@01-H`0X4-8`&-NB:MUO1VHQO5J`B/T8$)C"`"$$Y`!"0,81-%@(4A=K9#D=MX"HC.$R;MA5)`J$`%JF$-KU;%&"=I^9EH^;;@!TZ@)_^6L.O^>0"^HD5G`\Y+@0,.H0+KM+6@!"R@;1&E!!0O45PFDP8L!U^!@W]"`#VI`X(MJX,`(IE!P+UV+SDV``Q%HM301^L.X(^.`!#Q@!AED:-B9SV('ET")4V02"%CRC!0;R(4K%.HF7^I0]"#KBM*=A#8Z-":"X?U,930P"!#J"`Q[[P,9#%C18E?/\1$=U`M8.`P`&B/0WPA/J`PB]O\$_(N?`>,W?N0G@.17@%Q%?D:&"/>$"##0M?Q/``-X@B5(51*)(C69(7(``_4`2V"###YT[>8/\"9+@ZG/GN@441![_L1KI#@_Z=0;UK5ZYT50::EL!]1>KT!8:U@=OV?"``TFB_\8C]/>U`!4D``'L`$$\`F0-!R]0"/G@"4CZ4NU1#DO*I)+9I!)[MONB;ONJ[ONS;ONZ+?N2KI6!%FF+%#F2EL?*`-AVQFAX;1WOS`2.0C2?[`-S9MLBZK.41KG5M@`#[@`VW`!$0*;U%XLQPY$Q5``'3P'DI0`&V0`>+!#W*P`VPDM!WO`-QG!`/>P!T,;`C:H$>UW!CU0`B=S!ED[`&

V#@+C_8`VW0!M[0!B7PM`6^Z#CBBIQ5`J95*#,@080E`M[W#`D;P3'!H,K/#(+O/_BA8=Y47``!TT1M;*^::";@`#G).YOBN#OI=U8IE".DB(.W3*B"3-,D;L4P7`YP>?'*&Q:P:D4YM6XGW*,/"_P*)AKCI0[NI-VR%7,B!HJWS$Y;;*AMH^:'>M98$-7ON=:(JH#,*M0IL@O4>[T%YJ_6%[#U-C,G-0F/&3+BM.R/QN\N\W,N^_,O`',S`_#'BZU*TO*89Z[/RL(%TY('^6R8$`,`C4++9B)TCMT`8_8,`)P`5QP@0^,`%;`%6%Q@#?C+(IN[)M\``K*P=ZQ@0"@`0V!"ECANJ.GN_WT+12:R*6';-\*+SS.M7B0Z>_V3:`L%5&X0`KR@O/-A9"^@`08`!\D!!P8`,#J:RE:9-;Y7O?SJKP56M`P&+1K0\Q"?UF`YFJ^YFRNYD$3,C5B(S`-6M\P'/].Y^#,CNOFKB(TLW;I;I4ZUDZ;JZ^R[`(BWTY"X5MT/#A2LD]KI;OY94*_]1VV;8M%BCL&1WF20J^CA/'!N6QG;E:S@PUM,U4'IS-L`6;UT`>-TT6+($M#/,E=Y=0H`!F^O/G%*1#CUX7NO3I*2A4H)"B_/3I8,R'+\\^._(>==UTBE+BM20$+(4ST!;":OUJV)BCPQ!,,U-!!:3-H]11I#)*V8&E:==#!!"/\P$$$A;)Y?,!88P6R&8EC5S!13(":,;7,T61P>%\4YM3I&:U9)TLHTH6+;.[V6G4VVL,38'8V-L##&CX"5>]>.MZ-I@;H\CC('#"""L0(`:"$2@V)&/O;$"!@Y,UB\&FU6&T1-'5(F#&CI@$4$$M9:A!P`B#&/)EF(N,]D!IDY"8&EBLK5E*MMRZ,ENM8U."21\&U>`LNBN-$XQKW.,A)CG([,A=A.+C!'F!@M7/)"@QK*H`,QI.T):8-/.KQ>JZ@=E8%TD1.2ZAGU!=K6K&&D6J#N.J:EWM$P0>;110,K6&U4+YECE?S9US].;6H.($@22E4`'+"!`!&2D+(6S!5&$C`JM1+$;`C!*`(LN#+.7^`)%FK!1SP9NNMK=;@5'JK@G$XL'LHVM36U6?/G:\EA9=L[Y37!Z^ZP3R``27(`$N\HJKR'Q21WM>5=_WO4E^.P7@2GPM!(1R""F(3A9D(5M(HC2E`B)(H$6Q,FDB1*0B'09QO!M$@=11P83$K8D+V"#3R7!!A1`!(WU%%RA+!$5%=SG=A-667.'679W9%]EZH9DG>0F2$L>%>REJMAQ"-B$>8^6>8AVE*@K&=?=&8^C="SOA*R.:$!^`5Y4=KK)=^5Q8G03ETV16=M]FE5)[B(;R$'UU!K+@#_`/A8$@-U/Z_2!`:E$9S0B;+YE35X9Z68!"EPD!K"M=A`562(@G!#54(^&0/O"G!59?L\)G_?9(M-)G8+7E\688ALT+N*I\'DO/W2N%I?V28HR_9DJ44MF#4JF"&4?ZGF>#`%`PZ@`"90&G07I,Y)I#V9I+\!E)ZJ"DNJIZ3*24^ZGU+JM_P51R>%NRM)AN&]=>&.ZI:+8MXW#JS-!LYWAFNC8,#%B``4;8W/'M)$V`M/ZLSKH=E[QJOM=)NY+O*.2INJ^^$1`4L!>_5'K1F5#W(V@24J7Q,U)7$V/]`!"](2`_1O6Z%]M2NAH'J*V"=0$;9M91+!9D*MPFJ2LFNME=NMISTH(H9:WH?:%`]B,ARE;H,%XM,"F8@TNXKZ5XB`L#.:NS(A"D&@A!U.$[[RI60RN415N\ZKNY]0IXM09GF-&:MLIJE@=97,FS>A)/,M],RW5DDE!6[S>`GB-X,O$^,ORI[D%,0`$`$#$M-/$2!;(@"=(1/7%;^$&@M3HJJD(`'7`V"8**BZ5HL;B0&YH8">,P8N`&&&.GMS@GX`S^X`X>X0T^X1!.X0`.EV0B(B,"ON'(,>>WKGG-S9:+U\A=XO.]@IX`M?#0AE7L%*QN!`P0:=JUY/RMYF8^YF=>YFB^YFK>YFG^YA>3X;N=,1KCP-CLLQ(4W]P"JB1>XL=]XJ"4`5@9ME5C7FP50$"7Q/D]@H"GPSJ]R&04F$UOS;F%#$[UJA$KH(7&Z,&_`V9EU$(KAMO8^+`]02_[D=Y0X)K;G-"0*>'ZRMO'][?JK4M&@H4ZHT-HV:M5'8HDQ@DP$#CB8KQ(@AM\"42D0,''`E=1+2HT:-(DRI=RK0I4Z%0@4*:1*#2I4P?.WT:2;)4RY7.:-G"M=Y2)F-_S%LCZ'Y%$,ZU*S4Q/)2$*&[G6X4Y5D+6N:@/RK*1#=;%P;M^]SH3K>ZU\UN=`-0T_TU;+GGK:,=>S*)HLRI/,=[9MD;'[5^R$$>M"#NT',!>&+4X/MUCO&7[LO>UL&6D[G=?SI6>5/BGE[OTQV_R&(NBN(N\2(=^MT(O`&(QV*(C$2(S#6(S(*(BBF(S,J(QLV(PJH`?'&(UI:(QM&&>`B(B"B(CS-4$NY(RS')1RTEBS0TLJ_^5O.?)S-D.J[Z#R\MSSS-G(JET-RP7NR\[FK$X*K+TTL&U6NFA?S+^UJ;4L`$5&";4["V7\K,MUS2MM.F;W_NFPNFE,QW&MJFG8)K2QBFG)1VLO-FLS1K&4N`!1C#3X,D$_URDINQ"FW0+"S*-4R@Q\K4#3W7X8G4UBS1A8K_L$DZMRW4KR^`ZQ$Q0FE`*L+79T;TLV9(MIL/,!$*P!)F]V4(@!'&PFU+)_:4\V]?Y/:2`G:DQ"M0T.M5:W>0#G:)8K=5&D,D%MO,G=OMMUKNZ'[(%:SN7*[6MOON/FKM^SW#I0KGJMJZVAZ\MBO5>Z$#,O+#-M1G-Z`*[IPP^V6%MWNXLI>_G*3O^DMPTI:^FDUO^C]P[,5;\[@M!7$PM!4\_!;5NX:S_^R-OZ2>=\K\O_+B]!3>L3H%%)-W-:9NT966S>&:-.J7`"#(61:$/M\[;2)1-)E*4O&MC2*`!^(:@!W/0_^8&BH")MVAOL`TH8P1QD3_L/3,'I1ABL!T*P@>!8H0@WT,`0@B.:$7SAK3QH_@9@5@0>M;`'B5HCO\\,/@P\8+/M3,$(/:B]8IA-]#J_H`0\@1O12!UWA5/_K#93``Z#7M/@0R-W4XAWP\,`1%@'N/(%@\$!P?L`%]-@H`.`5SL`$0T&H&0&MZ503;-P=.MP`'P=0-9(%71QP,J\0&)QG)4^#"M(%B)U7Z]2&D+T'5DH'['>!].T'*UV(F098O&9Y;F&0(_M9P1$%U>)%E=6@`)QA6FZ>`$ST'P?)I,S8`538`-QQ00%*)?)MZ&`*!%L4`1TM8`!8V0:0N(^WZ17BPV:R^336&:8GPHXS1IL`N?^E=(=;^;@VZ*@_V[*H=UIE>@&$R@Y\XUFPF9H^9F]9MN+MG>!$S)L!S*IQS+F#S+I.S)KXS+NMS),N`#0``%$2``-=#(M1P!3^``M,M#(J[S,S-S,I@P%,@#-4##-U%S-UGS-V`P%5]`!/_``-``%=,#)I2S-U*P%MTVS.T\S,M-S,T,S.!0`%(B#,C2P"$M#)RLS.T?S,X^S,_+S,H_S/`!W0`CW0MM;S)_7S0J-S.^ZS0JQS0J\S_T,V\SN+\T-E,S0^-SA6=T1J=S@C=T;/LSZA\MRZS\RKR\RP7-RR-MT"9-T)BL!5I@!F)85%O(7/5`S"Q]TS7@`YSU9GI11ZW!\FM_N*)^E84_BC88#`SWA\N#N,ZON,\+H4L/KFL.6SO.)W-MFR',X,'FV3QQ>-,MWN0?/H1$Z.`1(FLESN.H\IN64.4NDKU.\>%4SN49S"K00O\*F,&QH_L+*=5DM$PUB^YG/"Y)*\?9EU:]T[ZC;UP;/+=1WBB5ALTTT/74[U(EMJDY-6RIFS9=.13_442OPCW.GS?G+VK-B:*7,X$5=P$QMS0B6H&%,3-&-8H\)*-@TI(Q#F#&*R-58A:5RI)F`Z.NI>Z;6G"+*C9(XY).LHNH1@4`W^5-W&T,BOU&`G4CN)(1HIPBH5T7S\(U[CO?-!^OO0.MK&I4'J4,SUE[3(J;+H>YUYG1:3WSB$Y&IT#C-+",M9DCLZ2IQ!*5+':U$EF6J;#3,IM6N?B?!U.^HB)X0?LM$;7D?BOKFRL@PSW-]2D4J_S4AP@`C$``[`end

GRAPHIC12c59872c5987209.gifGRAPHIC

begin 644 c59872c5987209.gifM1TE&.#EAT`(#GT-2M38:8KNS;R%5SB45IA]G:QM?+G7NFR%%126AZC7R'QC0;M9.73VR)\U,F@AR^0FC[8)IW5!!J0LA-6VUK4)A:UV8SM1W]*6K.%5MYPKTD,T*EB`+`H6NFI\+3S"S\[C)_:YN'V*E4(F&4-6%AQCU>X0`:G'P`\)HBT)I`01`E,TX!BS``H=HB(B8B(SX?;9(M`%*Y`UX`BJ"X`PF`E5:)`1APE5:9E02P`V(9EE8IEF;YE6B9EF99BD5IBRO@MED*Y_XMQ:0%#8`%O&086$`-#$`9#,`1O*92C2(J"28JC*)5H()4$'`8M>5L/%9&6=ULSB9Z`AFB"9E#7=8"B+DJ4(L`'@UF*.BJ5;,FCA2D"M-OJCCDF4C2F91FH!.S"B8:F5"="5(I"-^\6-L>"-TA6:=X9.':`!N98&%'""M)O9B+0AW(&$,O!!5JHA4\T$%:#:]U1==E!`Y_R!E!`?92#M10P21%B0?;8P'V&W"[9"?L.`#'88-\"0#3?$:ST`!MTA`C90?_B!`F8E.!G$M`30@`KA@+`>"+?@Q3P.R-FIG8]3F3V_76;=#4+MC435"@1=#)7EG)6;`@$2&M(S\A@7YG@4MF=Q?H!XAW6QP5>/66/4BP92RC>3(S`8L!@YD$M>B!(@W"67:[!4Z9@-T>2',30,`AD,D@F9QV"A5A=--Z2%FNE6&39?'-`#)/96C=;_MF3T`8.XW?P^@*J4V"^KP)M8F=YJJ>M5RG@!7OX$)_R29_41WVK\D[W\)8D$)=R60N+.%BKL`JM6`:("`(WZL&8S"^&U1AILDA>LOH:BXY883WF:*%'1W&NM`1#_`0;@!6=6`PP(N`L(@F%A9@&0;LD96TS@I#>);G.41Y)[44]&@/?*4:!KM2(]G4GUQ/FAJ4FB24FJJ;P8;7"03+>@($O'?FMGD>55+(4"4!@";O5^])&@BO,I06NMNQD5\QH\IM@O/''"]W;8!M``&J=QP1G7;M$&AE$`+Y4P7G7M!QA;O*S_N:[XP_`6Q%K*I=)YV&]A%[KX2->9)F0*IFNRV!4^USKNXB'34F=&ME9PM4,ZESPS'SQ9[@[U+VA-GVF-)T!AGT&;9-:)2>VIYAF^PA5T;`BT-W6ZN!C:]TB\-*--M!':N!W0+8.=+O>5+W-9;-@_`8!>".:N`'`VAES9LIZ>3YP^(#SI]`@PH=2M2D27?K!M18RG0IBE$H-!Z8>D""!!)8MH4!YP%6#5S%BL&+E`+9L6!X7**@-@B4(#AP4TF)YZP`'"BYX>X3HP9=OB#D;MC*H93)C.G3MZC.C1\X=/GL>/U52I,B9$`2A*2$RH.@$%!2PVL&!1_XOE`!-P5114YHMZ>=>/_>9!0-2J&5B1H1999!^`&&VPX;*'II7/5Y0`67+C`!0M5@9=M8`(0A>C#OJ,MI1H1",J4:F*Y3Z7N44Z2@QD(0$DPQ(8H9:E;37JNU5S:)X`9&$?`=E'$@':@9DJM@=SJ%63/%[IG'&YH*+ZW*&7Q%>-SPFM&6$,\UF'BW'R2D73!C(:1P059!."#+B9:./>7GFM:TULR$\"H,JPIEF5&L=XT6'APZC>42FB0\BL8,MMQ7D$X35/XB3#$PJ_>HW>91^TR4X*$",H`@J[0`A;^B+!>3=?VO]A%'FF-Q%NMR%FFRHFFRRE[U:&&+;9K=%/SI?]&5K0G0)CA`,:A+F80O3F7/M!4`55Q+I[%`Z-AM2:93/=5SE9@E`Z#*%DT;&T,KH&HQBC)P`AY@`TB+J>.+OD.[?D%`OJ$1M::%M?ZF*30S*BJ_%+S(TJVM9J_MZJQVRIKSZ1Z?6(/B*MP]D$9,P04HP`;KIC%EDM`/]P"0V0,BM#3^6A)1&R?RPV@M8J7@XU"N7E3H(;0][:7CT:KC(XKN(@1$50M`.GO4P/^B`!C+CY.6_LY$W>0(>'@+O`BX0\RYD)V3V]Q[X^_SM_P](J+LA`@L!!U4$2'MC\R_P^T>B-"A`XB3*@D5*F3(G"#"M4H7P@8T(YU$9G.J,VZY7FE*3YMP?86\@Y#(>PU2608^6X3H_,-\I:X1%\5TDB**SJ`%WFH0@:BD`$*B*P".SI`M%?!J3!05>%FCI2MC&4+Q(?8@G5G)YF(S).P`K4=T=^9B\;S7M0V?D*]CY$N1#708YR;Z`GX4F!J+Z=0C?O4SFHK^!M`1ZTX^#4;)%F5:;`SV[3!0[LQS^^7%J>)=!]!R&'N$CWP`06!(7D(`QH\%4=UY(MFZ2M\I%0'%DAN>8PCJ(S+D3L:^O]^7L$[ZD9)B%=MMBX=YC&>'Z=*8V097V5,O[Q)**?I6._AM#R%*QR-7QR-BAWD>*Y@#)3`^/9)CMG-E'3BA8Z@.:4KAZ^EB:_HB:&"-P1?0_\![OI=EHO8R^4`CX"1.M%0>'O3FC;44%P!E_)3`%*N,"/T$%2],T(ZE;,J%]S^E;+(22WT>=.,>2!%!^M0DJ/K)`VW_FD*$`8X?DF>147D"`4FF:4[SF?2LF43>E_PK`!J+-_&`:-=&"?I3Z)S#M+3;!E]=6:A6V>YK!A%`?&7&FNIDS/I+_#M\*N#\FN">,;TFZ6$OJPA_BI(X+MI7[@!.[0#C@\*?!@N9[U)/(>]!K+!W#K;Q5L3[P9P,'"P\3%P`X$!$$#3DB%^4X+`Z&6=]1$&F#YI`_(@U-1$O4WHS0O.^2Z7KF:`4KMM$L]D!*$^.BCM2E5"BA'\VMI3G=*:2%2"H@,H2;)`0`2)KOBU1`A,`&SM41.):M/D)INX1;/(+2M;L1M8\%;1CG*EBXJR05SZD)L6$((0H]"++/QRF,E%M#C"'$8-\S+2K44&&,J>"H4BFMJH-=@8TI9L@3X8C+`OP3@`&(`!$IG`#*S1'M-HFLS>[\Z!M'!L=9`R"(\!*(.@NXZ2W=:AL3F;HBPS6-@;&*QX$P0#"ND`BM=3?5WE35JL!90G&D)4GPA&>":!$E)8DB2F#H1XSZ)A,*5&@CM^$(LX99I_*BM/:@P`E*N)U1E"AN.JULBMB&)WB6XK;U0N2K,X0#ZU>^M'63$*1)RV7:?_"[[B6Q:S%MQ91)H59,0(5%J+(PHHGECUD\@='@;(HTWH>YL#>;VWS1:,Q13M7"F6O=^1'+M"^)6=FY)(S`T8666I*ID"$EH@!:HSN$9PJ`G)+@"Q6&0?.J,]R9=Z6:J%Z6=M+H`DKBWJ3K1UG)91X?5I>;-U7$=N(V(FL``1/Z!,48H9*SEBY`8V7R&+>6H4ZSH0+F4[YF8*7%=RM:5!?@M&]X0F(*YHLO2HABV!`8@4#J8')^1G"@241+E-VNQHRY>=V1;.%CM9$EZI$=J>JDDD9,E"4]:"@E2/_ZQ``1PA`Y9_P3\0H98N*5^54R[N9L9^9MBM,!D+0)R750Q9QHXCF7EN$1W1@0$2VW&FP2(@%S`ULB[F\0[E09,]19/N=%R$M6C4"H5N"!!GZI$[OI),E%!(W9*@X!W12`E=7,RT78:DY.`]'.`7K>CE+!Y6KMJ)^CRI\!:*K_.8L!>D59I*I/9*`(.CCM15H+("&UNG83ZCBB4&LB#7`M>A*MQ1E`%2NS$CO'RDA&Y1N&YZR%N7C9`)Z)*:/60J/]=SPC%H1NTT2M&ATNM9H_AP6XJ!@4.R1@UM70TQYC0/M?-IK.P0D-;0E(MN(%\&3"=&,$N$D.Y496I));MC4=0M>D>]S*'1&F14P0K.:"1V'=1]/JWQ&FO*1EI'B00+5DK:N2OX+&F]/.:MHL@%ZZJG1NN@.,L?IR6I3KF5WO`#0:`$1U`"M0+"*(KL+O9`\MCAAN;B+O!@B8OD$)W*6IR2SQU@'CKJU5*-?LZB9\-S5%B6CW_*O5A'=8P%M33QE%*8*5!``604$)6,"38HE"]'7N5/BKDP36J"P$JTKO(5:J+8V!NV[A=6ZM>R\$N?ID_[;UFT_XBX;Z&ZYUXQGY,V(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$QB\U;V%R%(!S$MR1PG1Y\+?P,#7'*R@CKTBA!G+%@./`]!NS7XXXJSR*`T$05#5JN:`D#-:0"+A4QERBA0;)9QD!9@7M/13N$*`5P,#T&H`$&;YU#*0\P1/&L$(KC.$&)SC!&)*`!(N^+98/H`)'!^91MG[CLK"6Q5#M]F5)@HL+]!M9/8#.Q4!$'9ZU/BQ9(T(J5_\9-*/I$(VGWKP'1[8D`1+?E*'T=LA!L;0``M(M+PD5Z*I,@W$%GY[R#@G+`80[[Z`,O2-QAT-L-?=:&N-&+`0T$&KWCF:`"M7B">"9:;A,`"X`JGO($1LAM8+^3P!@,@@Q$L0.3O2B"\'!65+7%)8G!0\2;KM->W6*GO(RU+QQ@-Q>NF*\0G"%K^4@T'`CU:DFX[_"/_,'EPME9`LFF"VGP0'8M_Q0B/K4'_BN?&L$E24?C`4OW`#+4!J*&4,)#`T3F7"GT5U8P:9@F4;DW`+GWM=6'7`5S0`1T0?*+V-@FG=LBW:O]G#2,0`9+%7G('7ZN1,27X@J$0@$23;J)2M,@5X@!90_U%M5M23:3MNB5R+`'A%F8WM=DY(`"BKF8C(G_`CJ@`WBP!PGYE14Y,#5PB7/S`C(TM-S%@9#%@22LDB@V%A"8IC19XE_Y(!F8@E600B,#7EX;HC56HE8+Y"PE#-(V9MF[JYF[S9F[[YF\`9G,(YG,3)FY%I"7K@$SJ0`4ZP!,[YG,[)`&P`F9+YF%M9M=&B#D7.SF=_5!FJP;BA$0S5$74=X!=%8`J;9CQV@FJQ)E4]8!C`IFXVE:K4)M#'GP!T0#G?JYG_S9G_[YGP`:H`(ZH`1:H`8:!@BZ!%D`F7B6I023F@!FW`0\2S5\K3;TE8FGR(@1T0``:0E^ZYC?$Y7E6(MD(%9G[APGW^@_P/%F:,ZNJ,\VJ,]6@0H0`4HD`%90#0-B@?+"0.0B1MUH`-$MPQ,5>IV5>9$9N9$5T`8]J=XFJ=ZJIAU@`(VD`5U,*/J6!L/ZIB/>:A..@]0M:J,[B9TA4S+9DHEFV:$Q\$EOM6.J))=?"J9("`9DJJ*KJ9>`!2/JGM37JD?T"LAGFP;V&ACGJ&D9H&&TID/5"IT1-8?X5[)8F>Z7D%GHH!WRJJ5B"NM,7E\YDJ3Z&H+!WNR*)NR*KNR+-NR+ONR,!NS,EN8?%`#3?JGO'JD>D"LA[`'MOYJP4CJE9UB`:V@!#]`#U%IC>[64IVF2)7"B&FL&:-"QK;F!']N74DBN(BNCM)=NUB9`'0W"S@(JLE4`T.L`'#\JH7JNL"PNIVZF11WN,1FEU7HMU2BU*KJB'@NRLUBN7+NVA"L(O+H'>5`$1.#_$Y9@MGF0MH4;#@O;K)+Z76M3M/'Y%74TP`$MIDM2(DGP+7M>6WM6Z:NEU[N'B@N(Q;MDCZN#"@MMH1;0L]@,1T/`EV7+^1]#OWMFX:D]IUJ('NB*)>Y9Z)\>,@!4`%=P,BD*\0EO+X+/,%#H\F\W,N^_,N43!*\M,,?Q"PFAK,L!*)903+D..ZTWC)3.^,IZV,.PG`.S;+Z-;,L)7,9&S"F7K/^GMX!S.XHQ\ELS)M^#)Q?P(Q_S"_*+,>RR6^/L"7N!U7S-(@RRMIO;()XS',A@2XUS0!GW0_;$6`1T+Q,S"TGO'7LLI3_S.8YF):X,$-3:>_E:!MI%G(%8C(UDS+Z"O$IVK"[-NUWBQ)"+W2++W2(;'0KH#.#NW"`BV#XT714FS1M^]M"-X!7'`W`IJBW^RS28CRNHX++HJQ/*IVG`M/43OW44!W54CW55`W.@`/3MK-#02OS0R.P[#D#1!$"6VYN61OE0U'7/`?S!L%P&_"RJ?'G`)8W4NLPD31)_M!'/7>)W7>KW7?-W7?OW7=PTJ!P-2N;P*,KW5-!W_T4-STXP%SVF8!G+C8B"9ME'&)A(5LER40`&PMTGQ9JL5WU$5;1B,9%A3;,Y8)5R7^M2QPA+)"QOFS(4H>>E+3%DP1:4R4C*DZR?S:NB2*#4KV+#G&@L>/IEBG9IT/MFUG48@5.T`@&$>APD9K'P@8X"%TPS!(7:Q@-0L$^N36AGAT:P!7P_YC'!"1@M#GML8`EP,(`!-*$)7_B-4CH@O>EAT`%4$(8B%3K$AH:0IX`-+$4KZA,":'()M',VE1T&)TE26]+&P;!5D5]G8RBXVERPE1;>`"`SD"'-FQ>35,7$:#F6"+;#6M:"(>U%%88XDO=T:9II#,=Z^W:5$-%E`##1XEGW_Y*2IW05Q=!C0)0D1(0E`]M08:,%("V"@9S.!#9`L\Z!STF0',A6.L_`860S)IR2"N%1UCC&&8X=:)"QC(V$/M6MP0%5(YGCJ'J@R-?Z^"6;+*Z8IWDJQW(4$65C`.1`/5'-7Z+57C*1E()2!&SB(WZ!:/0$!3G!?M,C""13K4*1A`>(]PBRN6!`WH)\I8M.6:`9/SG576P%5Y='!@"XAK_&%\H%"?)F>7`J182`$\*DM%?X*$.Q?(5A,`(-,`&)G`"E[`IX\06#5,_=WH_4`)4T529,`A5``ADH((**T9CHXHX[M/F>5R]Q+9/V$K&_YM'TY:[F]Y[NB>5'2_S2&^'Z_=!"?:%W03>H00Q14W"N^=QR+KYH@K'7OR%"'2KBR^/'ATY,D`(X_;NWCSWC4(MYV;(34(.'B0M1D(;"Q705(##AYH-(`44D858D125`0`0LS[.A45%-1=5566W4U3`U@M=/@@Q22==8>M>*S5%EYPR467767&*>&D-%M`^J-;V2PC?D,Z(HF'`))V`D.?;C&NFA@0BB;$$4F-M&*[01@B&^K0%6B2"Q=MY(`KOPC0,K`E"68(H#Z1J`]R;A^_^49M'&1*#AOHP`-ZR7J,91F#VSPX!XDV)C"C16D/=TO$4ZMWYU4\7R]UC;V!P?SB`B7EF2J:4`.SFA&Q#>D1$1">VM&AO0!3.PA:S7A5S"9;.W;+4WAK=7AA!W3KRGC%'S>Z\5$43\0'?AQG1>57MUPPRS9E1)P`8.9`'.$`D6MT%-`Z23U(6Q=%`!-D$6TP`6&9&HS58P$8&$FN'`(N54JV!`ZT2=$H@&?9@:(MQP1%I'A$Y!F?9V*>`1LED&W?J'F/YP+$5!$4\2@&8'K_\DPBP62KQ(Z(&8]QM*0?:8X09;:?H=1:"#&:"Z%FM,T22AXB2U!51MZ%%+;5RFU`>MZE'`N(-:1"2(_E]X2>D0ZJ2)9PAME@KBT-[S2`.Q5KZX+1]TM=HB352%`C"O(D1M)``S0D1T)`T_P`5ZP!,4'/XQ312:Y+2UE6X@V+H0R+@,`M!&81'>'8EV9CG:9A)K&B4WHB4:9F(K9%T.ICZ:WF$\L5`?A5K/KTS6Z;ZE?/^M:[_O6PC[WL9T_[VMO^M]JY'_:I_H?OLXO[WP`^^\(^*6`?.@TX@118@19(M@:^G"9P7"6QW"JQW@2`8@B(X@O['>@.XL'F_WXUAWF@8(`V^(-`&(1T\X*>X'U">(1(.(*J!X,7B0>+.$3=YF7?MF7?IF7A+D%7ZD`,1"1.;`%6'#_!%/`!!H0!2D0!7GIE0J0EY=YF95IMF%^9F(D9D8D9E@IPEX?YF1)YEZ@YFJIIFH`9F(.)!%U)D5N``8+IEZ"I`!B`M4_S@#N1#/D.PEK=8BI/0!B%)DE-IDBJI!500!E&@!^IGP]`E1ZIE1I9!!99!&R@D2!)E1;`E19)D1-)D0Z*D18@H%RIMD5@IH5S)H!%I`&;E68BH>PBG,(D8KYH`-*H1UIE150G"?9HBZJDA*PMGO/9!N*YG?HX_Y3]J`//V),]>89PQZIS*&0;LJ9SS.9]R,)/5>9W?*8\TM68]@T)TZT)3*:H\Q^8\T6I0T&I7.204IV:M:`)\NZ9+QV9(N&9W=2O\%4?">M4AF2',F1%6JA&$FA'MD%#S"2"7JA#CJO$)JN`UJA!2JO5:H`%E"-KAJXMH_[JHT#ZC@3IONP[CRHKLB(;E#$I!4UJKC3+L#8;KUUYF#L[ECV;I1@@CJWJMO((;O8R0>FMPM$I[P4K[`FO*`&O+IHAIJ%.;IE5;J1J,M24``H2:J&?[M6.+MP6>JP9\:IWG)MH49_P-RB[5(X+8)4)@R'`.1NJ9Z.@"G>JK78U[.([\?=\HJ[+,"LMM$,#^."^>^=7BN!GF0,(O=FM^JJ-C`AT*.$3?L&5BI@=W,U.:[;LK)BC&:EFJ\%@MR\)>ZZAH>^+*W+6,79@WS,.>2LZ;FNR-_>,__NP[G`!R2^V=>IG=#.U;4B-Q_C%0BF0M"Z[?WFF/7;5F9AQO295$\OJ7T;`MR'[`$S>-&@Q9D60,ZT:U*LMH\0TWE`#%EL!=%5..-5`D4D45HT>%U4B28X0ZE@.!DLG_-18L0,J"1U$]MM38:MXR14VU'!5)X+DL)F@@_G%(^X\45S8SCT>M;MF0?1)15`%',E+UP(4/2?2/,1>X%H5`%L:M@0$54`*/P`0-J`60T/\!1,`$"G`A&Z-G'%,;7H)$0[9P94)I7G@VGG>2.N5@4_DLV&%?"2;+07=4@62N($*/8`G'D+QP(J.-(13E]%L`&"9=Y#G=D3?EPF8AVX%>.GAANH&B5P3&7YZ6:C7#8UG%14G-:611HI86KHD1@F1JWG-^5V*!01;VMT.6T$M!35Q"ZX)"]!`'BUF`*C".:.%DZ*".8!$B#;FJ(DT.LXGGYKZ7UJX1$2F24BVMGQ!G=E#YGY8Y4`)*H-8B!L9QH`O`95L6`217'4W@!ZTX"[_T2R2@!+NJ)`4A0_P$@$"`:,"`MT`%,D`JFM4`H94J.LI6?3Z#&-"1HE4PA;4!\_&IJ?YF2A%F5%6B7X95_CQ6H-A6L+!5%GM$2(FIC2,PC-4JIT.I8-:JB1Z9PAZ3>`$SA-97MMY$90E[@AL*#@0!"FO#`%Y'+201'F4U->I,"53G:2QO`J2T`D2]KDZ?5H_,A*H.EF'AKJ=[O855G55WU#]X[LVCTR>B.0J`5``[T:4QC:?F+R;MGKIP1&V_H`RUOE/.I-R_2]T*6*N5"[`M6A:KU3$%UTL+*@B4*-79%`+YT2'.]ZALYWQ"(1!RL?B_,$3M?@2D("C,BT)HUYL(Z])B0&I=$EKYJ@R_4Q8`&$U8_!KJ()Q`Z787X"E7X_9U"4MYGZ3%I5^63285D_VQP_^B40!^EXDLQ88F2H!(`=0D#=VHJ!_D@DA-5*3!&L.M:C=M0#B+PP84.C9`08%FQRDSQ:&^AI?"!J+X&8*`R1`$MP`E0%0.EH*ED3[JMHSZ)P"TID`2N6@,S"@,T6J,WVCN(1RV51(1.`*2B68,YJ`-08#VH*2\])AYQME1Z:F@,_P`(_\`4*:R94,V0$$V;(0HV!A!`BY@?;C_#),WL7C2('>Z"R?Y0&T`IRI2`)J@M`WA8`+Q[G'783#!29ZZ`D^[P6N.9LO)0#Y(XB4'3JSF!B1LJLT;IGI[XJ$HYMGUOR:$%GJ5T3OOK94%C0M9TJ442KE1DG:K:P#)RF(5_I)PJ*K8K6=;'V*(,CM`25TJ-6;GKJ6H6`;MG>0#'ZF$M/=@SN5AP*18@I2^0`+6Y2Z/!N0OIK[@)L/$SK`-;K&"C`RY#,>&4(%T&0'$3M0H(GQZV`;_`ZKD)5+TVVJ]N%Y:1!6G5@"TQ@^Y*D1QB9X6>'9#2VH5$"?90!?01(?>57`?=7Q\-D8M@`MW;$'V4H5ZKC,:!W".1@`SQU`PZ0_&(0SC_B\+:\/!5!0M!T_P!`U`&E]H&KF^=Q\`""DQ,4@@%2452$A'("5,&E$/$B!]?4T?'WZ631$1M#`L)#1DX.!FCI*@M!`1.3@5M/8,$6J?"@@*Q9M`*XB0..F[AEM3@AHD5!AHL4N6K;=1$NK5JVND[OI25P:KE"`F>*HNAC`(8B1M&ZZ*2JD$-.6@'MG-`(#\`$1IXE4:$+PHT/?8!+W-_.1S[U^5IXJ=B*Y3+70/W,X#]Y*+JRARLJ2@=,$53AC;MU24!GF0`Q&E5%TXR7.+_%^?=`C(>F8T+`)96ID!BO\_E+AXGE66(7=%GHH1WIP(UUD)#-@&!)B8#ED&&/P]F%0%6)SM(9MZ&(=MIF]KU7LI-CDI%A,=%(JCT@X&A)`'PS$E_3TERY*-K3YI=KF8`X&CG#`!G2YV)T,1*6\5%W%!.J:3.M3IM2(_3_U:1-$DL.11'T2JT`I[D>3OE^9VNLI.L&)D/M0\8(!_O5$POAYFH2`^;&6A0(#"(YHYG$H_RM&*7TA:_\2E]18R0#E(SS])JP"5-8A%-51)!FDX6AO`UPDH/:5HQ#%"R1`@W@?(?HM2=YIB(NZ_Z@EX1>X,I-(YA2'S"LXH!CE6SR7D;[R2;2B\4`M>K7'Z##O@;54FS!=P*[E@XXV1!LRI#5R%DY68UML"PWI$&Q,@C]UB0X[@Z*_M=6NG1;>F4:'6RK6KH;%>%"E>]I5Y,V9;NB)+_K116N.XV+*=RT>N6ZC#BC&-M\P:N\:%Y=7/K5F6S@;6AM"%*1"25"0]`#'AOP"0C$MH$:\>8VZT`!#Y1EA@W\R@N'*-$`$#946P`A`HMD3JPY0)J^6P&(R@!`B&``@":K0+?8P0;*J"#!10!!R"HP:/>AAMQ,0HIBQFQNL.F8$`!=*N`"_]PMH`#ST2U8(#!E#P'`R,L@4"@$6F%/`#;6V`"&;H`510@(/QT2T3IL0:W5I2M0#.`H`5@&X$"/H0V=K0``_N!00N462+M;>"8_E/`L;17`1AT8&P0V``,%`##M!@H`!=LC(P!&0**EF=)JT8`!#'10@1`9-8%B`+M+5B`#-2)@2)8;0$=@)918`"6+O0@:S"(JPPNX$!K?H^,_B/+!L*W@1%XH9HPMX)ZQL$8]$M&M!-4T5A5LHH,6H*`)(>C5;2JP@06LP0P=".W2-L`^&12A`3^XM`PANT@,4DJB@&.@`:F'@@*9$=@0S*,$U"#`JRA!"B8T#%[Y=&(I8NADNICM$R_:$(I*AKR5@]D?*P7&[@JN-.%3E!TOJ4*MZ%'-JVOTLFLR&B$MJT$Q$O-2;)(Q]1A\]FA(!3)B@M0T(B`&)/:2-(,YLQ`I+W#_'2>1'2JS88MBM))P!);Q0"ZU1C1$9/.H".+DG8G4H;OT2A)4)AE_$$NP_NJO0XNO^&JRYKJUY7JM+LNUW7JSPXH$/L45W8AK3_(`:W`2*ZWPBH/;#[/[`Y&Y;##+SB.\9;M`A.1O,B[O&^[O,JKO$P1O0BRO-3+*R5@O=I!N[7[CL`+O$4I#;R[N[?'!C2DMNPHEG]HK>>0K".5K-N3;O?'5&K9[1?5&NHYA#MADDZ@CE*ZK4(^RDO^P/JCWM#XV[18];P(TK,W,88B"3'BXA-5,5*1:!&1G1@@QI>`EA;P_BMW+$8;QK:X"TM8$^%2/JPF;B#N"),F@0A5W)NXJ9ZM#U;#>_G2#Z*4CU$.^+"2`*S/`G'&2;P/U@;0:,)?Q7Q`*D*%"?,-630Z?F,8M%WV_>_%Z'_;$/5@9X"'%6L^_L+AN=UG?6S2>;E]Y;M=W4]XZ3"XH_AM9>-A3XVTG[MZ-'2C(/$@6#C]M"-'CR^AQ"T@"AH^SM*U&O=#*RYEL%E\\'[GAMP-'>!S8;__0U>JE'>_A5;"]G>_UE:MX6M>R=G?6N71HH(6?Q'(>@+(;EE&ZG@`KH`W$'M9H)';SZP9C)H9II5:SRH8,9'8G*68&EH6X5'@`RG>'R89PM(A@FX7%#V@%+&M_UI=>'$:)VZTMW0$5H56"'L%5GWV56!+F'4E1VV-QG)_)FK3QX)'EFV-9GZJMA82FQ6\].'09IGLXB(/!UWL2%H=JMG>GQ6XG=F.+Z(E`EHM5]WS/!H0>R&D4M>(F4B'6L-H)-1X6.*&DK*&"9N'E:B'F':&6&V'9H]X>WM67S5W^,9V_^AG?ZMMW\[AWMQZ&9^6%IW5H"*EWB"MX>,9XV/-X@P-HB0YVZ'>%SBUF36-5V,V'2YMF(S**',]5GVB5XDUMW',"%S"QEJNAP$JV'R>:(PGAY`X=XH^6(JJ&&&\9H.KMR(JNF(-%9XJQ=6+3UVD>R'RZ"'O-1F.D%FW'IF-0F/^)G7A?U3>%`>:/1`9RMJ9:/%KB%3%:/\UAQ%,>%?>:.N76&S]6.\G9W;JAWX,AW(`EPKA4$08`#5$F5M/A`$GAH6>E:"I=PR_B!+?F2!9EMX6=BOA5]QL5=?@F)_!A^M!\E;I$B1LBB'&YF9-$AKPJ=S]X9E\S5MD\B"D$F9I:6227=]-'=YJ3=?LG>+M_(B,@8E>5\B7^GB/)>>3^364:KF`7P:(N"4&V8A;=79V,7A_)?"-2KF4!D#:>#_`73WFWOH`6FPA_`8CW*96T.0!@M'7=7U7+1%M!!Z``^]X`6TIB&*X:;4U!.Z9!B@0`Z@'F[FU77[)8LTWFT*6F(4YDNQ%;+6HM8D_7BTJ(P@I8Q;9E$[9D3G(F9HI?!Q*@^/XE*N5FD,H8`X)MF>"W72F9A"6FH&['D/XJ>XQ:5VF@,G-I98&5M8F717Z5X",*C#CF,MAILFZ:IW@9[ZE6Q#WIUM$WF[97B\GVNR>*J&N\FL]GF2Z;H;E&MC`>8U08;L`%!W`%!(,MM\,`EH`%RH`'!/`1T(``;P3AM/`;/[MV`72VO@WI;B:]?1,0R+]Z[G^VA]L0M!/6A/S#@U2HCSXQ'`R>%O7Z3Y5HNG,2=?S()YF,!&DH`!_)Z=/4EC%XWNQ4[MP19*"(8+GBA7+`/6&\"W-D=`W7DNWAGQ.K4"105F"N>-1DI@!XC$H#DP#$PDMA>DQK\ZY4P_\R2N/9=A@TAOZV,_,02/N>.X25#-3UM:LZ0CD'GRN3@'WY`68M(0.5"J,'JGYM,'.$;-7F8"BRUMOCM;;[R="PA=:GZ$A80,:@DD&A2--(T:CU6&!15ZA!!J$\&6^-*%M@C!LT*`QQ4RC3#(BGN/).!M*-^@U)G@"8HA1H2%=&-IXZ(DZQR#C3#3LI!##M*/]!S!CB,?E$QHXO!,YM\T43N\S;A.BK@H5Z;*E=(49KZA%H"!@DB/%(?)!5OE!E_3X0M:0AM9.#.F'C"UW+"7^N@$@/@TB83"4";404*U;*LKGI>'0I9D!;ML"M7^,XM2P9R2@&.N7B01#ZRKM';5N3U6?HFRTLR1,PU$`WOH8AI)V3FT&]H"#]0B;R*%PA#1VB'8ZXM3@"B+95A8&!.?61HQE;DB@`T!1`E:0%"!1`7)D_W?D-PG[$2?#`$\&IE-;%SPLMQ%.TZ`F$$BS4[UY90XBAF27%VFI5&S'EFI89E.6*+(V5?I"M"2\EG083BNC7AX]#F'XHF,BTIWS*IZN!&SPTM:4#64"WE]"'?IAN>7JVB3EA,5O$1OR'?&H!L/&0+?6'%_^Y!%C@$A:W-!H9M@9+IS+`M$8?F$3R[A/MXA+O\E)Y@W9KAE%REP'\@@``@RM:VA'/0>"+6X!+_PU(>I1-2.J54&A4@9?^53@M2Z2`+WH$Q$@,F-7,L+^`=5;,"4W:0'L,U4&0T1_.&="19>'$,U-8)MXB!,?@"IT&P:#!@$L+5MJ;19-FSIIJ+G`S3@E1[D#"^`+\JFQ955K>,A'4*3ND'`75,V94.C%F8(IU$DM%\9R_QRG,`K5>11;U$WCP@O].':+L1C?$0)*@6RE$0*CLZV\')Z>]+SD,7W3MVTV5)"]ZT?-W!B_,8BS0M`*^S"Z^3`&=@`4@;TBZ9TE9XTE-ITE&*8_MS%NEP3Q/L;3.USJM/D43UF1M"1V`8+Z#)5?G,)\KF%,`N@U029WP%F2!+E7R*,I1#2Z@)?0!UM1HA6\5;(J`(>!%"1(B2#`(T8&"+%JV]QEV3?O/+W_WZM[\`_J^`M`TS@`1NXP`@^L((3SL_Z*77=I=+WV6^]/'_G+8`ZSF,?;YQ":V%AM-:$\SVM&Y@W1H`:/GN%93R$->\6ZYZNA/^_K7P`ZVL(=-[&(;M^__8OW;TH]$\82Q76+>[YC*&D4WM:EO[VMC.MK+C$&L)-SL_`(VVLHV?W#=YIZX[K(^3WR80-^X.D'.76]*A[_>LFG_K2%6OU_`2FUK:-M>;T!K>O1;IWJYXS_OI6?GNA7A_Q9M2K][U!.?]WX(?V(B&F(B(N(B*V(B,^(B.&(F0.(F26(F+F(5$*(9]J'R`&(B4^(F6M&(J@.(JB6(JD>(J.B(G)QW+/AH68:(JPB(JR&(NT.(NV.(BJR(FRE8?,1'``!Y`!T&B0#OF0$!F1XSB0=B&1%GF1M&)F1&EF0#K>1'OF1(!F2'+E#`.E]`DF1XBB2'E2MF$23.)F3.CF1N;:3/OF3/UE-)3F"WV>3%:F33("0+ZF0#3D'=0"44!F11GETM45F55BF18WB56KF5\XA10_F+13F5=R&32;D!1)`!S.B29PF-=L"5;NF/8BF/M;SF75BF6='F75;EV7[E#P!B7-FD'=E`$79`&1%"8:'F6:-G_C`Q9!$7@BW[YMF)`9F9(YF919F99YF9B9F7K9BU3H9YJY=H$)C2U@EH5IF,N8E@JYEHSYF:S9MFJ[YFK`9F[(YF[3I8U,(>IY9F_UR!TG9!1G0!;[9DBU9F&EPF$NYD&RIF\JYMG,S9G'5Q!A=0`'C@G-19G7VXES;4E[,)F-SY!T5P!EVP!&9IEFA9GAMP`$U`M!TVPD(6YE$30!8UIG?(YG\RY!%R@!`&@!GB1`UR0`W91`%S`!4S@E3B@!$NPM0Q`,-L0`^S9C*F)EL\(F!8:HS)J_YD2H`0YP`10,*!WD0-*H`33N19JT*,ZMND,;TH"^``;44!![``9\"2+UFB6JV,&;`!+:`61:":C'F8YLFIRGB::;H$M=X!IU?P'4/#.\^P$=UZI=WP]:IK0JXZUK&=-ZT./FDRPMKC/K:LWK7ON:TK>.1ZGC/)0WPC[B`C3K5#[@>"G0?2@P``WP!`ZH`R]PCC,9?IO(@"\@?N.7`O-8@%`7E&(IE(LXM:'"6;DC9C3Y`=CY``D-WCPK)`CHP`($HB!('?L,(B@.0`HE7BN'W9V,9F*PXME$7)2G,``HU7=GWH>":@A0/0`1:@>2(H`!J@`0/`;@-`D^@X?EW9E"/0`=$HMF*+)@X09D"\V`R@@@B7@`T17A"10`1CY!!"G@NTH`$]P?`.P`B0@`"60_WBFMN(R@")JC.9RM6)IG&69SP`*(>82*N7TF,`1NF0+MAH+SB(H/8'L3@(Z\R9E6M((+S^`6A29SBZ7S&&6E@MG_=QOBG,#`$@?JG53"BAWJJS9:H!EJI">`"M[)>:)D`#(?"`OKFC(R`"E"D`$CF,$H=^/BJC;2B`?SH`J%JLB%J6KW:.K9H-!)?"#`[ZXB25@LUDH@A-07Q*P14QP!CRDM3CT[MJ?VLT$U`PA``@V*LD/@!BGG>W$*!',)?A,@B!G*`,*'@A/`%'?D&GBUFKMD29'`AAUL`01)MU=>\!5DM=5_0`>Q';WBE#!,)!_%K($(L5-QD-0@48-L+ML(HX@04>L`/:O=WX`$]L$IU8`'?[=U8,-A_P`'?_=U]@`5N0``$X`%]M`-])D``H"A/.+&SK6T&:U?3'.YW$B`$&[(`="!7=/`'*O`*/EX?A;0`1Q`6B^`9=[`"1?#BWC$4?T`!M0G`9$$`'$'`'"]`$NJ``#P+K?R`$`.`/%P``A?1$FY$$3][KY_T,*G#EVOT!MNA#L!#`%/``0N`5S]#J*G%4?_`&IYX+_5[_!"L@ZTB""PN`Z[-.`MZ]TMY!2$4"C0A`L2QPSNL*J3A*)##C=9W2!`D&`2'F@:M)KD1\5O+V'N4M3V72RZ`&-R@X)IR!M0;,PD3I"M(KJM:)$LBA``:J7AP3T80I,[IRMVJ%8HO+&PL'U\C&-FK+"RM00VCZTH0X`F`!3("`#5:0AL>L@@E@MD0`%;"`!P2A@"6($CBA9@`UC4(0$\^``/DH:"&CW$#'5XM7Q*6Y($9[*L'H?2`#8X@!PX0;3B?JT,>7'DO=SFM:O=K8OZXM3^ER$`[+#C*MF1PX`2Q:Q5NT#!YKP5S(8204`JI521P==I/_5W8KE(\(K"!)>R"I(SQQ"K#8)#-^/D3A!'0X`0YI6$F```35@=J#V;>`V:DK1)VOW86C#M.A_6!%&1?K`G-S%6-W:34>Q%1;8&.'S7=_7@*3A17[T&'9>C.`)P;`K87X]7M&5;W>*H!%983+=#1`&%P`DIX`D#%8`IF;9XS5++1)CWP8S*@@46A86HG1,J!M>B.F_WKHAF[-D4+N=H+N4%8RAE8Y=@C]MDE_50!`IGOX`+10EXN5I'G-0_SEB/APGOG9RD9I:%D`M1I`")RJ=`]L5!E,JD,M="\*ZL+-IDP']\*@1\>:NUMJ=X?7PD)'RWO\"UI:0&2S$-*#')MB6&*!V(LT-)B-]76USV&M^!6W^YFY^W\)MSN=LT#C^[#5;MKS`,0_I9%@;?\/8%`YEC[/DF\51?]:_ZX^%[E5J]X&Z&V1^=QM7.\1[O\=F>MO+)^X0;M[4&=\F^NZCK/\VW>ZJ]^WW*NUBL@MOQ^PV2U0RH@?\(Y]M@9_!XOP\(5P+3!&`A6OS(B$R'V&:'E0MV(@32`:02`:+Z(=2B(%ZN'I9N($@B`A?"(:X-H:@.#EEF(:D6(IFR((YUSIQM>"]\IH-\=X4V("`:&F*F(B4AXB^V("3V(2..(R1*(F\>(N9M9XFSJ(&9J(E=&(*>N`GT%(IB./^*IGB-IHB*"?4ZJV@OK?A_KVAN>&B`2ZB>2(TE;LF62H]>2=LEXP[AY(;"7M?-F7?OG_EWO9B/88B3Y9F(9YF(B9F$&YEXL9F!-XEXM'EY(YF4M9F99YF9B9MF9K9!9S9!5(YE5!%?RHH3EH9EJ3XE5YIFJHY?!1EEOJ"EFF)7&MY+R;0EFX9MDJ=EDG*):9.9DI#9DGG9!(`YG,,IF(-)!HJ9G,JYG#S)EXT9`A3XF[TYG:.GMF=9YG=C9F9Z)`Z`9F@PVFFZXAHKD4ZN)AJAYGN4)D3OEFF>4D;&9!+-Y;K9YMF\^7FW$Y6W,YF;\)G'E)G/[9E\8YF,PYH`2*F,Y)DP#ZF)!)G0R*G0[ZH$NIMG9_9G:))1#'WAIWED`:5GEQYGF#I@JF9GNO)GO?R"C9Q\&J1^6J#_2:0W>J1(JJ2&FIE,MZF!U]*0(U3^E&996&JF2.JF46JF6NJ5G.*:F0X,NE#)MH9%KVH-MZJ:`)Z/WM*:>O1:=UBGUW2H%Y^I=[RJ:B\6IF)&E7&,XUOIJGXMQU.J>:G(FJS*:JFD2*R2IZC]0N9JKN8P'N(Y'M:!+M0]ZM/+M2#'MF^NT]!RZNIP).,P*LM!CQL//.3PY/(>58TG0B^2E72EDIBBIPN>5"RNVKYN_M#WW56/W(,K#57"T#6-W57!W)LIO5$`W`:RMJ"T"+NX5?+]I;V=S1+GC>)5RYVV9@J5T]["ZN(H(=I721+!;)[VS:7+&JFP.\D+S;]BT.=]WM\_M'NB"'N`\_MNZ^VE&WEKJE^1*#M=^2WH3S-P0_N0L*^72;:E^9%*^VTT8*UM2PCLU67FF8`>0!>WI_CIIYQSUFGN@,L4J.>ZB2G6I[C=RB7HH!(6>MFAB':FM:#V,-EJ::9'VT,-N&Q'QHL%@$&'!IL\51>K#$$[3PZ2+)[MZ!OBNG_%Z,R^]E-G;%@)@APTVHV+3M838=\NPSD!T/I$8BBA-*\=V=2JQWW0TWF3)&OGK,4C#/.*=Y"\62Q$VHET5F.N&`C>U.`O[#I2I);3F4T)_Q3?Z0D(,A;`G0D6#$JMKQ,!'W"WO&DWI]HWCZ-\C#0X/Z4-:9,VXMG_)4>S$-B`-RN0$(40C!00`I9CM)P(^V@>.X'RBX*&UQD)-U*`;Q]I^0]'JA!"^#_]QX5J$?C8611VZJ`D`NZ1JER/Y#-EWW'Y=+DME^QH@!V`!'@E?1D3P]_7OXTUJE'/S2R+]VR`2W@M$V@],-[SR(GQ"@.UV3(1IB0$$:%=;[,8'YMY/=NNS5:;HU?Z@%X0=-K2M%1I$@3R"-&\DEICA5K/B1ED\+0G+1'8S7$M-.>I9MT&@`(P.(-0XCQO0GF_\$2&@[/?LK/NO7L&/+GDV[-FW4RE[CWHU;$^_?OQ4QJT:\N/%I`$\#>RMF[CGX\*9BT-]7;D%[]K%X1=OWLE\^_KY$]O5X$%Z]N+\"RLY(E]Z%%$D0*$PMC@*!>`"8*#AR@)J3"W140@HMP96""HP)I-\*)\#3'0$F/$:`"BM,)=547?^EM`,$$'":PGQH'L=65&A`^$(`'7:P0%4`!E8700T1Q=E9W:UG8U0DHM%0@32^]M$!B!`Z*@5UIC':;E92I6YG`^4;GG84(EUQRQ_5YW)X8-),.AU$G3@2$F0XP`]A[JST3W@F=-./"N&!-!Y]'S3%U2=S0@/`6R8M8$!U#@S$TWX$^>=`"P&J@4(*+/&'0@DJH("A2BA0*@\!)^@$`$Q\O0./9R4$M211WR9_P0*&BV]]%);%'0Q@4TVM^:0;335!D$("./U(DTUHP$'34T?=-``F+T`P`90Y1:"56FAUF1997H89EELPM74!!!!YTD0`*>.@EV)M\^2588'#NE=B=ASFFYV.6]>GG99X%*NAGHQ4J6FGKMR3;.`0-5\N>I[T'MG`9(!$M)"J@P`6VNE7WJ:0E$\`.!'ZBI)S\!`TG*$%V\#``IC1%E'```$HNAB4(H"%7MFF+E!:PT@:-4Y7U:K>3,ADDF80Y6F+[LBF%7,LR7?LHI%VP3-(MM)9(;U=4+B)(!E+M70#\8!.K7Q#>C1*YGF=*5P&@#X.\UC:PS8:_=2M=RU2@)>X8+[V@`VV``F`;%QE@1-WT3?.[GNNZO@=[_ZR_,Y--EM#!(R.Q*S)E*.WCA`U#6YWHY^*#>3GM=[A]B[?]/%%EM5*LR=E.GIX^SNJZMBAX5$*3^`S8^A8&*XSE^$8I*K_$\Z^[.MK;NZ[>^Z_2^Y_)^[_][-;#QZUSL/&\1WO\43_YCS2M+^(&Z^%K\G:.\B__LK&,"BQ/J5__]?J._]!21_-T[>&Y4`X4QD?DH//A&F+.M#M\+C_#3CLV#RKJU1_15N^TPCO2?KO07CZZ!'>`\H,[TJS,=Q>93^/CGKJUPMCO7"I/7`SO5=']!E'\.R+/9C+Y:;[_+UV2LPV=I#&_"+/O#(T0XLLO-M88'#M]7;8O-&ER_?_J^U;*_AEGND8[=]IGO'K+!!KWO=3[_%N'O)H/*?/^'3/_W%6`S$SN'JB_K&Z2>L'W;AF@^P#SVRG\F$S??461'>4Y_;RC#^X;E6;2,-2'8>'#3OED-L`M"JUH$DL6DDRB]]Y\]]TWWGOV.=2?.=VDM9E0PF7D5-EJ9U*BC7T$]*:4"G86/6FQMBEZG=(&ZUV&DF@H8JZ#2U:E^#R'AM@:R/+8Q9%4_FZF5G:;/]:X)`/>)"`262#$03RCJ+VP(ZB-!:!@=DH.WRV4Z0MKBMJH)&!B`LHM]QL#I!,"A$,O.LC-=S52V2D=B2Y`K_]IC=`P`(7)H)\+QB,M+_$3B>,@VJ%."$R."1CW[$MN)+8ZU'@L8,.I\9#=^@P+!^QPZO?W!DPA6^%`M%`PW*%7C$X("%@OP%;0P"(?F*TQ!`270%J-Q#X(F80*8=G14@/VC5&Z7@,:SM@!\W@3$1!"&E-R]!B=!@@9SXHV`(.I34.A;J9QIV4PH'`:#B6PIWG^`BX"`8YD(+0>:N)PH)ZP1C068LO&QB0X0AM.!5M*!JY.MP8=A_P./C=JG#=E_;GTMMJ`6L"._@R!7/2+>;J4VXH7MC^^@"*\D'7D,)_J&4OB26?N&8+M":+JJ=OD($ML/$SL24RT!8OP`9/-`C_^(Z`M`@QEDMS%D8QG$>6?*0-@D4;$R^N,@(W,09'-,;QB06A#J'TP(./N""V6>1K!MTH;,;14W//4%RJ"G00%2(X_3;8:)_0:#6/#;_KW=[NWO*>YO&:QZON:%$1C@MO9R:'05V`9_?/=7'^=-['HXMR^=K3H)1L.]GCJ,_"9^'D';+*9=RJ-,L#S0N_SW`J90!&HBC#[O6Z1?GC\S@&8MFK+C.W>VW4@!IE&1;W`:C>F.+ERW[U;]S'@:4]&F=$K=#[HLVB3S#!P:V/V]M'=_^[N_8X>CVX.CW4CVDD@((`V-:6E,#AX@#$8N,BX93BSV)M)3V+`Y41)5H16F,18(B;524E8)R)J`,E;WY^411W=Q0#+WYL`P!^!S$Q!WX0M`[XO`U&MMZG(RCL`-!**Q99MV/H!0$HM:XMN)5$Y\FHV'DGX/>'$ADLO'!!'M+N2ZE0JZZ1:T[B1DNJO5)OXR7(46A/U%RI(E(#PO)T,"3`HF1D:!,_$)EN:$L_0`JKRQ-MRT9W$[,XR=%!O`&WY%MEJ+X[1?5(AFV.!B'9ZTH7"7PROY^%3:?U&ARE5.7741#N]'UI3$'_V,$9D1GM&D,0Z76=NXOJ2N")"$AB=;.#W1%K=Q>$A::(4PI8D'Y')D2,J#]B2-&*6E2/$M5'-K:#)7:\Y8MCAYP7(.E=3?3(FJ$XQ(2LBV-*;V\\)!"'>+XCWF54%G#C_Y"0M&8PAN9B&7M)`4GQE*ES&)W^7B\8>WY4;0"UFU?V8?H8=-;-F>D1IVM%@_2RLH&KC8[!C.2T56D/>V?1($-8&WD5RUFDJB$#406BX%64_(&--FH!,T^M0%A!:;$H;%4K,7`)`'BB"FQK5:PI)=.K;WEI3(=8TW?)ZE2(.CV"[;A10U$!M`"]P(C$R?3715^D$0L0`"YQ%M/#C>S[H+-`ET-EE@B)*3.HE'"N&3K)E\0$D`MS3B4=U644S>-MU"-E?0QW`(@)G%O3V-C,8!.25$AY/@V$Y043!$55R9N7_25M[2B6P!`,Y(KB6/=+_EOF(2@"8-7/Y*0GW?8R(/'[@3R0Q%E^4.+ZDM52C'DALQ?QM!F!3)HU9@`#9CJX6;0-@F9IY12`3%:E2@AO!M"F=1+=06DW0VDZ-)FJ5Y6CAY=`ZVFJV9H%Q*E1A:$M"JG(M,!^8)`.]%`6!Q`MO`THC)*NX1*OT9:M!@*NI)&[^U$LVAK+N-H$!=_]O0\(+TGHA+HM*M,,MB#4L*-0LBO,`+^LBSLM1L`\,+(M>OC2%P0WNS+*NW%GJZMRCL7JMN\@LNZCNJZ/`6[NR.[!4O_MK4;4+W+A[D[N;N[O>#[2YI%O--KO!-*MNLF[O.I+`,[;OB(+O1TJO6?$3=:[N-FKO>&;G6WYO?G;O\9%OO-KOL%'7K>%MO-BUOL3FOH/K!`S!UL`0K,>8G,D/MS,>36UA_[,.WYP:B/,JD7,JF?,JHG,JJO,JLW,JN?,II$,NR/,NT7,NV?,NXMG,NYK)VZW,N^_,O`',S"/,S$K,NO?,QNX,93FV>1',6M1/"#()3J:IVE1%X*T_3(]*FH"Z9-Y;.I,_0O$#R?U!'NB6PD-K)L"M.C5O.GQ,@Q_LX`@CCKFA[$%\X1?*HGY'"&J@7(A-V$@1CYC$`O%M,][1(UVRMN))234A=E@(MO+D"A2M`8_!\S3K"JZKT^\W>8QKWK,?7CXN)5Q\8/H1`6?+L3&@Z`'&K@]U%YTALB9$8!_B*FQ&+'I>0W.R-9JNXB%Z:>.MZ2@(0,B.&L@.$S=OZT!G9?:([X9]\J9K85B,6)&29E@`;.AX!0!O)O;_'-148'AMWM!4'0EWVI9D/(#%M8A1_9BX,Y""79B+*1:_5G`1O&!\U(CR8V@&0Z^$D87*(&HZ7$,8`$#.J!LAVQLJ0)ZH!/$J&PUPF843J(7K.)Z0"&^71W^#>6M"P)X[*9G]1YGZ1Y/K8)/UMZ6_WR:*"(``G,*546J56>J58:J41NR:!CC>-UFF?/*J-@@`'2C45`:!#%RB2`=>1@J`&72B5@D!4RM9OOOJ@M;HH01H94)$.A)5GD9EG>(70>8-0N$SKM%)1`0E`/H,[M[B7=X2@N(%7E:S'N8*0>[F2O#,T?P6TRS/U=P-]#P4;SD3EKI?E>B_XOBEJV>`%6C.5XQ8LZS.7\7.+.'.M$!>^!%&P%7``('T`)V`??B"4'V7/_[`-7"``W+7/49H$22"4UPO0%B'0`YW/MTSU6UL``4@#0G`!5L0`5^\R]NPU%:`,H#$]RN`Y![!*S[!;2[,XN"]"NO^CN#63NW=^]M!5)/TM#;!U.^YLNP*U_]#@_?].?>!UQ^[W"`\/OB#`WOYLL@`'>N!YZC!#F[M#LP\V7=-TOWN!_\N"`&_Z/@=M7V`S,KPYV6M#+O2]:V!Z79,^!1_=LR#\;`YMK`'(!QTO\X(P@M055UMZ2"M?4O439YN``^TWDVI>OMHO1@_C`0W_V>LS:V,?$Z]>!?(`7XQ;4!K(#BFPV7%Q^"PS*$TX`3$MGTTG`'&97CKG%9\YT]]*\9C9/P\W"A/-TMW\4H_>BK)7CE#P:2D`3_`:"RR`605J!G[3X,;R&O1`&K"A0G"X00-`W*CMP?/H@^G7RQC@(!PJ_A\.]F]T)VOD:55T`H4M_[W$RZ1T*2J2$J$H`9/3+`IT3Z($.X=@Y`4M2@2X(Q0)5-T/##1.M.0!>GO3BIGQG1N>=*$R1N2&YSUD3W'$$/L(%C.:$?L"$Y-8.%6KA=7,A=.L6$(&\&8"D)P`CCQ7+B!97D&>Z#%BLVX?M"H)X+W9908>P[!$,6(C.LG%*W(CG3XCO:H!_*H97`0$BLH%/BH!Q6QMCS5X+U2Y`_$3D/$WD'58D*DP`T-7%%C`)G@#;5UF3JN-Y7B3HI+`Z6!S'!1$0NX."&GIY%)TJ;%V:-.B>P?+'`$+MGM2%M')DL./YJNE)LW&TGJ-Y(^L9L3:RM6CDM=2:LV([MF2;HCFWJ&KF7T$KMJ6IU54:+_YA>1VM+&U"2`;"P)+5!]J16^YBL"+9[6UV`6K:".[@Y^QDK^B-KMR[:5Y;;:X6=:H[0#.QMV^TIXBPY4^[?I))28BYLV2[B>^[DZ>[;>FI:VE;B*M*USEFDY>B4*'.9.RYEE-.TKG2AD^$;NR6[6N5+GHH+>;^TH"($%^V[N#%;B@M6[S&^Z%!\D>0I1J.RG.ZR:+-&[WF@P?C^AH*QJ3&68CQJJ2"]3$`:[FN:ZY&MNKFO*KSF>[XBU;G'N[YB^SW*FR32JS;/NW/Q6[_4*[07>;U(>F03MJI[*Y/AM.Z.SB[DW&;+H>\`'3+SLN\`WZ[[FL[SB4K^,JIL2'+_W>[J3FO][28N]_KNYMH61,O5N^"#S"Z*O`#'S"B.K`:@/!J%'!:4O!+MR\%XS!^CMAE=J_V[C!PH=5MZ&"[17I.!4S"0MR[)HS"1ARH*EPN+)PVI#N_3OPCU3M,EI4._V9H8S$#6`8'MAMF)LRF3&B1!!>=-!+M?,!E=CHE5LYC%61:\5I7%;#S$8J:^1SS'ANH][XLDM/_O$>OP+40PE4XP.5:RJ!:`G%;#%="=VH.^90Q+07Q5A4,4GS.(